|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Zhong JH, Li H, Li LQ, et al: Adjuvant
therapy options following curative treatment of hepatocellular
carcinoma: a systematic review of randomized trials. Eur J Surg
Oncol. 38:286–295. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Poon RT, Fan ST, Ng IO, et al: Different
risk factors and prognosis for early and late intrahepatic
recurrence after resection of hepatocellular carcinoma. Cancer.
89:500–507. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mazzaferro V, Romito R, Schiavo M, et al:
Prevention of hepatocellular carcinoma recurrence with
alpha-interferon after liver resection in HCV cirrhosis.
Hepatology. 44:1543–1554. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
6
|
Chen L, Zhang Q, Chang W, et al: Viral and
host inflammation-related factors that can predict the prognosis of
hepatocellular carcinoma. Eur J Cancer. 48:1977–1987. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu JC, Huang YH, Chau GY, et al: Risk
factors for early and late recurrence in hepatitis B-related
hepatocellular carcinoma. J Hepatol. 51:890–897. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Imamura H, Matsuyama Y, Tanaka E, et al:
Risk factors contributing to early and late phase intrahepatic
recurrence of hepatocellular carcinoma after hepatectomy. J
Hepatol. 38:200–207. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hoshida Y: Risk of recurrence in hepatitis
B-related hepatocellular carcinoma: impact of viral load in late
recurrence. J Hepatol. 51:842–844. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Clavien PA: Interferon: the magic bullet
to prevent hepatocellular carcinoma recurrence after resection? Ann
Surg. 245:843–845. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oikawa T, Ojima H, Yamasaki S, et al:
Multistep and multicentric development of hepatocellular carcinoma:
histological analysis of 980 resected nodules. J Hepatol.
42:225–229. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang L, Wu WZ, Sun HC, et al: Mechanism of
interferon alpha on inhibition of metastasis and angiogenesis of
hepatocellular carcinoma after curative resection in nude mice. J
Gastrointest Surg. 7:587–594. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lo CM, Liu CL, Chan SC, et al: A
randomized, controlled trial of postoperative adjuvant interferon
therapy after resection of hepatocellular carcinoma. Ann Surg.
245:831–842. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin SM, Yu ML, Lee CM, et al: Interferon
therapy in HBeAg positive chronic hepatitis reduces progression to
cirrhosis and hepatocellular carcinoma. J Hepatol. 46:45–52. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miyake Y, Takaki A, Iwasaki Y and Yamamoto
K: Meta-analysis: interferon-alpha prevents the recurrence after
curative treatment of hepatitis C virus-related hepatocellular
carcinoma. J Viral Hepat. 17:287–292. 2010. View Article : Google Scholar
|
|
16
|
Shen YC, Hsu C, Chen LT, et al: Adjuvant
interferon therapy after curative therapy for hepatocellular
carcinoma (HCC): a meta-regression approach. J Hepatol. 52:889–894.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singal AK, Salameh H, Kuo YF and Fontana
RJ: Meta-analysis: the impact of oral anti-viral agents on the
incidence of hepatocellular carcinoma in chronic hepatitis B.
Aliment Pharmacol Ther. 38:98–106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun HC, Tang ZY, Wang L, et al:
Postoperative interferon alpha treatment postponed recurrence and
improved overall survival in patients after curative resection of
HBV-related hepatocellular carcinoma: a randomized clinical trial.
J Cancer Res Clin Oncol. 132:458–465. 2006. View Article : Google Scholar
|
|
19
|
Chen LT, Chen MF, Li LA, et al: Long-term
results of a randomized, observation-controlled, phase III trial of
adjuvant interferon alpha-2b in hepatocellular carcinoma after
curative resection. Ann Surg. 255:8–17. 2012. View Article : Google Scholar
|
|
20
|
Jeong S, Aikata H, Katamura Y, et al:
Low-dose intermittent interferon-alpha therapy for HCV-related
liver cirrhosis after curative treatment of hepatocellular
carcinoma. World J Gastroenterol. 13:5188–5195. 2007. View Article : Google Scholar
|
|
21
|
Kudo M, Sakaguchi Y, Chung H, et al:
Long-term interferon maintenance therapy improves survival in
patients with HCV-related hepatocellular carcinoma after curative
radiofrequency ablation. A matched case-control study. Oncology.
72(Suppl 1): 132–138. 2007. View Article : Google Scholar
|
|
22
|
Kubo S, Nishiguchi S, Hirohashi K, et al:
Randomized clinical trial of long-term outcome after resection of
hepatitis C virus-related hepatocellular carcinoma by postoperative
interferon therapy. Br J Surg. 89:418–422. 2002. View Article : Google Scholar
|
|
23
|
Breitenstein S, Dimitroulis D, Petrowsky
H, et al: Systematic review and meta-analysis of interferon after
curative treatment of hepatocellular carcinoma in patients with
viral hepatitis. Br J Surg. 96:975–981. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang CH, Xu GL, Jia WD and Ge YS: Effects
of interferon alpha treatment on recurrence and survival after
complete resection or ablation of hepatocellular carcinoma: a
meta-analysis of randomized controlled trials. Int J Cancer.
124:2982–2988. 2009. View Article : Google Scholar
|
|
25
|
Nishiguchi S, Kuroki T, Nakatani S, et al:
Randomised trial of effects of interferon-alpha on incidence of
hepatocellular carcinoma in chronic active hepatitis C with
cirrhosis. Lancet. 346:1051–1055. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sung JJ, Tsoi KK, Wong VW, et al:
Meta-analysis: treatment of hepatitis B infection reduces risk of
hepatocellular carcinoma. Aliment Pharmacol Ther. 28:1067–1077.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ikeda K, Arase Y, Saitoh S, et al:
Interferon beta prevents recurrence of hepatocellular carcinoma
after complete resection or ablation of the primary tumor-A
prospective randomized study of hepatitis C virus-related liver
cancer. Hepatology. 32:228–232. 2000. View Article : Google Scholar
|
|
28
|
Budhu A, Forgues M, Ye QH, et al:
Prediction of venous metastases, recurrence, and prognosis in
hepatocellular carcinoma based on a unique immune response
signature of the liver microenvironment. Cancer Cell. 10:99–111.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang JF, Yu ML, Huang CF, et al: The
efficacy and safety of pegylated interferon plus ribavirin
combination therapy in chronic hepatitis C patients with
hepatocellular carcinoma post curative therapies - a multicenter
prospective trial. J Hepatol. 54:219–226. 2011. View Article : Google Scholar
|
|
30
|
Hung IF, Poon RT, Lai CL, et al:
Recurrence of hepatitis B-related hepatocellular carcinoma is
associated with high viral load at the time of resection. Am J
Gastroenterol. 103:1663–1673. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin J, Li N, Han Y, et al: Effect of
antiviral treatment with nucleotide/nucleoside analogs on
postoperative prognosis of hepatitis B virus-related hepatocellular
carcinoma: a two-stage longitudinal clinical study. J Clin Oncol.
31:3647–3655. 2013. View Article : Google Scholar
|
|
32
|
Huang G, Yang Y, Shen F, et al: Early
viral suppression predicts good postoperative survivals in patients
with hepatocellular carcinoma with a high baseline HBV-DNA load.
Ann Surg Oncol. 20:1482–1490. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang JQ, Pan GD, Chu GP, et al:
Interferon-alpha restrains growth and invasive potential of
hepatocellular carcinoma induced by hepatitis B virus X protein.
World J Gastroenterol. 14:5564–5569. 2008. View Article : Google Scholar
|
|
34
|
Yamazaki K, Suzuki K, Ohkoshi S, et al:
Temporal treatment with interferon-beta prevents hepatocellular
carcinoma in hepatitis B virus X gene transgenic mice. J Hepatol.
48:255–265. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qian YB, Zhang JB, Wu WZ, et al: P48 is a
predictive marker for outcome of postoperative interferon-alpha
treatment in patients with hepatitis B virus infection-related
hepatocellular carcinoma. Cancer. 107:1562–1569. 2006. View Article : Google Scholar
|
|
36
|
Ji J, Shi J, Budhu A, et al: MicroRNA
expression, survival, and response to interferon in liver cancer. N
Engl J Med. 361:1437–1447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Suou T, Mitsuda A, Koda M, et al:
Interferon alpha inhibits intrahepatic recurrence in hepatocellular
carcinoma with chronic hepatitis C: a pilot study. Hepatol Res.
20:301–311. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Miyaguchi S, Watanabe T, Takahashi H, et
al: Interferon therapy for hepatocellular carcinoma patients with
low HCV-RNA levels. Hepatogastroenterology. 49:724–729.
2002.PubMed/NCBI
|
|
39
|
Shiratori Y, Shiina S, Teratani T, et al:
Interferon therapy after tumor ablation improves prognosis in
patients with hepatocellular carcinoma associated with hepatitis C
virus. Ann Intern Med. 138:299–306. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jeong SC, Aikata H, Katamura Y, et al:
Effects of a 24-week course of interferon-alpha therapy after
curative treatment of hepatitis C virus-associated hepatocellular
carcinoma. World J Gastroenterol. 13:5343–5350. 2007. View Article : Google Scholar
|
|
41
|
Hagihara H, Nouso K, Kobayashi Y, et al:
Effect of pegylated interferon therapy on intrahepatic recurrence
after curative treatment of hepatitis C virus-related
hepatocellular carcinoma. Int J Clin Oncol. 16:210–220. 2011.
View Article : Google Scholar
|
